November 27th to December 3rd 2017 ATHOS-3 Trial Monday Khanna. Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3 Trial). N Engl J Med 2017;377:419-430 Tuesday Dünser. Vasopressor hormones in shock—noradrenaline, vasopressin or angiotensin II: which one will make the race? J Thorac Dis. 2017; 9(7):1843–1847 Wednesday Basso. History about the discovery of the renin-angiotensin system. Hypertension 2001;38:1246-1249 Thursday Hessler. ATHOS-3 and the knights of the round table—the search for the holy grail of vasopressors. J Thorac Dis 2017;9(9):2788-2791 Friday Busse. Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety. Crit Care Med 2017;45(8):1285–1294 Saturday Kimmoun. Angiotensin II: a new approach for refractory shock management? Critical Care 2014;18:694 Sunday Bassi. Therapeutic Strategies for High-Dose Vasopressor-Dependent Shock. Critical Care Research and Practice 2013;2013:654708